Based: San Diego
Raised: $53 million
Investors: Enterprise Partners Venture Capital, GBS Venture Partners, H&Q Healthcare Investors, Hambrecht & Quist Capital Management, Johnson & Johnson Development Corporation, Lundbeckfond Ventures, MPM Capital, Novartis Venture Funds, Pfizer Venture Investments, Venrock Associates, and an undisclosed investor.

The scoop: The money is being used to engineer late-stage work on Mydicar, a heart failure treatment that recently gained fast-track status at the FDA. It also marks a major milestone for Celladon, which announced 5 years ago that it had raised $30 million from Kleiner Perkins and others to get Mydicar into the clinic.

Editor's note: This story has been updated with new information from Thomson Reuters.


Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.